146 related articles for article (PubMed ID: 24019750)
1. ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro.
Skoglund K; Moreno SB; Baytar M; Jönsson JI; Gréen H
Pharmgenomics Pers Med; 2013; 6():63-72. PubMed ID: 24019750
[TBL] [Abstract][Full Text] [Related]
2. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib.
Dessilly G; Elens L; Panin N; Karmani L; Demoulin JB; Haufroid V
Pharmacogenomics; 2016 Jun; 17(8):883-90. PubMed ID: 27268766
[TBL] [Abstract][Full Text] [Related]
4. Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib.
Dessilly G; Panin N; Elens L; Haufroid V; Demoulin JB
Sci Rep; 2016 Jul; 6():29559. PubMed ID: 27405085
[TBL] [Abstract][Full Text] [Related]
5. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
6. MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia.
Lardo M; Castro M; Moiraghi B; Rojas F; Borda N; Rey JA; Lazarowski A
Blood Res; 2015 Sep; 50(3):154-9. PubMed ID: 26457282
[TBL] [Abstract][Full Text] [Related]
7. OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.
Kim YK; Lee SS; Jeong SH; Ahn JS; Yang DH; Lee JJ; Shin MG; Kim HJ
Chonnam Med J; 2014 Dec; 50(3):102-11. PubMed ID: 25568846
[TBL] [Abstract][Full Text] [Related]
8. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
Vivona D; Bueno CT; Lima LT; Hirata RD; Hirata MH; Luchessi AD; Zanichelli MA; Chiattone CS; Guerra-Shinohara EM
Blood Cells Mol Dis; 2012 Feb; 48(2):132-6. PubMed ID: 22134106
[TBL] [Abstract][Full Text] [Related]
9. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib.
Vivona D; Lima LT; Rodrigues AC; Bueno CT; Alcantara GK; Barros LS; DE Moraes Hungria VT; Chiattone CS; DE Lourdes Lopes Ferrari Chauffaille M; Guerra-Shinohara EM
Oncol Lett; 2014 Apr; 7(4):1313-1319. PubMed ID: 24660038
[TBL] [Abstract][Full Text] [Related]
10. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
11. Impact of genetic polymorphisms of drug transporters
Madejczyk AM; Canzian F; Góra-Tybor J; Campa D; Sacha T; Link-Lenczowska D; Florek I; Prejzner W; Całbecka M; Rymko M; Dudziński M; Orzechowska MJ; Jamroziak K
Front Oncol; 2022; 12():952640. PubMed ID: 36212403
[TBL] [Abstract][Full Text] [Related]
12. ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics.
Barratt DT; Coller JK; Hallinan R; Byrne A; White JM; Foster DJ; Somogyi AA
Pharmgenomics Pers Med; 2012; 5():53-62. PubMed ID: 23226062
[TBL] [Abstract][Full Text] [Related]
13. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
14. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells.
Mlejnek P; Dolezel P; Faber E; Kosztyu P
Ann Hematol; 2011 Jul; 90(7):837-42. PubMed ID: 21225261
[TBL] [Abstract][Full Text] [Related]
15. Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.
Sennesael AL; Panin N; Vancraeynest C; Pochet L; Spinewine A; Haufroid V; Elens L
Sci Rep; 2018 Jul; 8(1):10514. PubMed ID: 30002384
[TBL] [Abstract][Full Text] [Related]
16. Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.
Maia RC; Vasconcelos FC; Souza PS; Rumjanek VM
Molecules; 2018 Jan; 23(1):. PubMed ID: 29316665
[No Abstract] [Full Text] [Related]
17. The
Galimberti S; Bucelli C; Arrigoni E; Baratè C; Grassi S; Ricci F; Guerrini F; Ciabatti E; Fava C; D'Avolio A; Fontanelli G; Cambrin GR; Isidori A; Loscocco F; Caocci G; Greco M; Bocchia M; Aprile L; Gozzini A; Scappini B; Cattaneo D; Scortechini AR; La Nasa G; Bosi A; Leoni P; Danesi R; Saglio G; Visani G; Cortelezzi A; Petrini M; Iurlo A; Di Paolo A
Oncotarget; 2017 Oct; 8(50):88021-88033. PubMed ID: 29152138
[TBL] [Abstract][Full Text] [Related]
18. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic immune monitoring of CD4
Lu Z; Xu N; Zhou X; Gao G; Li L; Huang J; Li Y; Lu Q; He B; Pan C; Liu X
Oncol Lett; 2017 Aug; 14(2):1363-1372. PubMed ID: 28808483
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
